Print E-mail
Volume 42, Number 2, April 2009

Human papillomavirus, genital warts, and vaccines


Po-Ren Hsueh
Divisions of Clinical Microbiology and Infectious Diseases, Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

Received: February 19, 2009       Accepted: February 26, 2009   

 

Corresponding author:

Dr. Po-Ren Hsueh, Divisions of Clinical Microbiology and Infectious Diseases, Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, No. 7, Chung Shan South Road, Taipei 100, Taiwan. E-mail: Po-Ren Hsueh This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
 



 

Methods:

Human papillomavirus (HPV)–related diseases, including cancers, low-grade neoplasia, genital warts, and recurrent respiratory papillomatosis, have a substantial impact on public health. The increasing incidence of HPV infection and genital warts highlights the need for an effective strategy for the management of this disease. Immunization holds the promise of reducing the overall burden of clinical HPV-related diseases. A prophylactic quadrivalent HPV 6/11/16/18 vaccine is highly effective for reducing the risk of HPV 6–, 11–, 16–, and 18–associated cervical cancer, precancerous cervical lesions, and external genital lesions, including genital warts.



 

Key words:

Condylomata acuminata; Human papillomavirus; Papillomavirus vaccines

 



 

J Microbiol Immunol Infect. 2009;42:101-106.